ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Ecologically-Valid Emotion Signatures Enhance Mood Disorder Diagnostics.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Mood disorders, including Major Depressive Disorder (MDD) and Bipolar Disorder (BD), are highly prevalent conditions. These disorders are characterized by persistent emotional dysregulation and substantial functional impairments. Despite extensive neuroimaging research, reliable neurofunctional markers remains elusive. To address this gap, we propose a novel approach that utilizes Divergent Emotional Functional Networks (DEFN), derived from functional magnetic resonance imaging (fMRI) in naturalistic contexts.By integrating naturalistic emotion induction, dynamic functional connectivity (dFC), and machine learning, we identified emotion-specific functional patterns in healthy individuals with an accuracy of 83.99%. The DEFN was subsequently validated in clinical datasets, including a multi-site MDD cohort (Hiroshima University: MDDs = 63, HCs = 111; University of Tokyo: MDDs = 62, HCs = 96) and an independently BD cohort (BDs = 59, HCs = 50). Using static functional connectivity (sFC) and nested 10-fold cross-validation, DEFN-based models (MDD: 70.33%, BD: 75.18%) significantly outperformed baseline models in classifying patients and HCs (MDD: 70.33% vs. 57.58%; BD: 75.18% vs. 63.18%). Additionally, DEFN demonstrates highly reproducibility across age and sex, supporting the robustness of DEFN model. In conclusion, the DEFN approach presents a promising, reproducible, and clinically relevant neural marker for diagnosing, offering potential for more effective and timely interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.